China Pharma Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2017
Filed with the SEC on Aug 14, 2017 and accepted by EDGAR at Aug 14, 2017, 16:08 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-06-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2017-04-01 to 2017-06-30 | $2.9m | us-gaap:Revenues |
| Revenue | 6 months2017-01-01 to 2017-06-30 | $6.2m | us-gaap:Revenues |
| Cost of revenue | 3 months2017-04-01 to 2017-06-30 | $2.3m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months2017-01-01 to 2017-06-30 | $4.8m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2017-04-01 to 2017-06-30 | $648.4k | us-gaap:GrossProfit |
| Gross profit | 6 months2017-01-01 to 2017-06-30 | $1.4m | us-gaap:GrossProfit |
| Research and development | 3 months2017-04-01 to 2017-06-30 | $21.4k | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months2017-01-01 to 2017-06-30 | $47.5k | us-gaap:ResearchAndDevelopmentExpense |
| Operating income | 3 months2017-04-01 to 2017-06-30 | −$2.1m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months2017-01-01 to 2017-06-30 | −$2.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2017-04-01 to 2017-06-30 | $142.2k | us-gaap:InterestExpense |
| Interest expense | 6 months2017-01-01 to 2017-06-30 | $281.2k | us-gaap:InterestExpense |
| Income tax | 3 months2017-04-01 to 2017-06-30 | $30.6k | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months2017-01-01 to 2017-06-30 | $60.9k | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-04-01 to 2017-06-30 | −$2.3m | us-gaap:NetIncomeLoss |
| Net income | 6 months2017-01-01 to 2017-06-30 | −$3.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-04-01 to 2017-06-30 | −$0.05 | us-gaap:EarningsPerShareBasicAndDiluted |
| Diluted EPS | 6 months2017-01-01 to 2017-06-30 | −$0.07 | us-gaap:EarningsPerShareBasicAndDiluted |
| Operating cash flow | 6 months2017-01-01 to 2017-06-30 | −$773.6k | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months2017-01-01 to 2017-06-30 | $51.8k | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-06-30 | $1.7m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-06-30 | $17.2m | us-gaap:AssetsCurrent |
| Total assets | At period end2017-06-30 | $77.1m | us-gaap:Assets |
| Current liabilities | At period end2017-06-30 | $10.5m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-06-30 | $20.0m | us-gaap:Liabilities |
| Long-term debt | At period end2017-06-30 | $10.2m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2017-06-30 | $57.1m | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001213900-17-008653. Last ingested by Listed: Oct 30, 2026, 16:51 ET. Listed shows no prices and gives no investment advice.